---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-041190"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-02-06T23:59:59+00:00"
generated_at: "2026-05-16T04:05:13.295292+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Tempest closes CAR T asset acquisition from Erigen; Erigen owns 61.3% post-closing

## Summary
- Acquired ERI-2003, ERI-2206, ERI-3003, ERI-3206 CAR T therapies; issued 8.27M shares to Erigen.
- Erigen owns 61.3% of outstanding shares (13.48M total); its members Angel and Lotus Capital to own ~35.9% and 25.5%.
- Geoff Nichol resigned from Board; Michael Raab stepped down as Chair; Stephen Brady appointed Chair.
- Stephen Brady resigned as CEO; Matt Angel appointed President, CEO and Class I director; $650k salary, 50% bonus, 269,621 option.
- Issued 6.78M warrants at $18.48/exercise, expiring Feb 3 2031, to existing shareholders as a dividend.

## SEC filing metadata
- accession: 0001193125-26-041190
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-02-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 5.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526041190/0001193125-26-041190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526041190/d159400d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-041190
- JSON: https://secwatch.observer/filing/0001193125-26-041190.json
- Plain text: https://secwatch.observer/filing/0001193125-26-041190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.